DGAP-News: BioCrea GmbH: BioCrea Announces Upcoming

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading International Conferences

DGAP-News: BioCrea GmbH / Key word(s): Conference BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading International Conferences 24.09.2014 / 09:00 --------------------------------------------------------------------- BioCrea Announces Upcoming Presentations at Leading International Conferences "On target with rapid acting antidepressants" Radebeul, Germany, September 24, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at the following three international life sciences conferences over the coming months. Dr. Tom Kronbach will be presenting: "On target with rapid acting antidepressants (RAAD)" at: The 14th Annual Biotech in Europe Forum, September 30 - October 1, 2014: Basel, Switzerland www.sachsforum.com Corporate presentation on September 30, 2014 at 11:00-11:15 CET in the Lima room and The Neuroscience Panel September 30, 2014 at 15:30-16:30 CET European Partnering and Investment Conference (EPIC), October 2, 2014: London, UK www.epicbiotech.com Corporate presentation on October 2, 2014 at 11:30 BST in the Maynard 1 room Therapeutic Area Partnerships (TAP), November 19 - 21, 2014: Boston, USA www.iirusa.com/therapeuticareapartnership Date and time of presentation to be confirmed "It is an exciting time to be presenting the BioCrea story and our lead program to three eminent international specialist audiences. In particular, we will focus on our advanced NMDA receptor 2B drug candidates for treatment-resistant depression," said Dr. Tom Kronbach, CEO of BioCrea, in the run-up to the events. For updates on these conferences please also visit our website: http://www.biocrea.com/news/events/ About the 14th Annual Biotech in Europe Forum The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies. About the EPIC Biotech Conference An autumnal event for 2014 when we will once again be showcasing the best of UK and European biotechs in a one day format. Some 50-60 European and UK biotech companies will be presenting and are looking for partners, investment or services. Our audience will comprise 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors. Industry keynotes will set the tone for the day and partnering will take place all day as well as informal networking. About the Therapeutic Area Partnerships (TAP) A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas). Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. About BioCrea BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychiatric disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). For more information, please visit www.biocrea.com. Contact Dr. Tom Kronbach CEO, BioCrea GmbH Tel.: +49 351 / 4043 3332 Fax: +49 351 / 4043 3216 tom.kronbach@biocrea.com --------------------------------------------------------------------- 24.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 288237 24.09.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automotive ECU Market Aims $160B by 2033

Updated Category News Views 1

Automotive ECUs Under the Spotlight Picture this: By 2033, the automotive ECU market is expected to balloon to a whopping $160.59 billion. That's some serious cash, and it ain't just pocket change. This $47 billion jump from 2026 isn't just happening by accident—it's got everything to do with high-octane changes in the industry. With a 5.1% CAGR, you best believe it's a...

Continue Reading
vivo and UNESCO Unite Youth for Nature Stories

Updated Category News Views 3

Young Creators Explore Nature Through a New Lens Pontremoli, Italy just became the backdrop for an extraordinary gathering of young visionaries. From August 31 to September 5, UNESCO’s Man and the Biosphere (MAB) Programme and vivo wrapped their 2026 Capture the Future initiative in the lush landscapes of the Appennino Tosco Emiliano Biosphere Reserve. It’s one thing...

Continue Reading
AXIS-Y: Global Expansion Fueled by KRW 430B Valuation

Updated Category News Views 2

Rewriting the Playbook in Global Skincare AXIS-Y decided to do things their way, not just because they could afford to, but because they believed in their vision. Their strategy defies the trends-driven tactics of this cutthroat beauty world. Instead, they’ve been all about climate-inspired products and vegan, cruelty-free standards. And now, after notching up some...

Continue Reading
Indiana Fire Safety: The Importance of Regular Inspections

Updated Category News Views 0

Everybody thinks of fire extinguishers as those red cans hanging quietly on walls, but there's more to them than meets the eye. In Central Indiana, these devices are a literal lifeline, and neglecting their upkeep is playing with fire—literally. What Makes Monthly Checks a Big Deal? Fire extinguishers aren't just there for decoration. They're critical safety gear. This...

Continue Reading
Sony Meets Hello Kitty: A Collector's Audio Dream

Updated Category News Views 1

Unlikely Duo in Consumer Electronics It's time to listen up, and I mean literally. Who would've thunk it? Sony teams up with Hello Kitty for a limited-edition headphone collection that could make both audiophiles and pop-culture fanatics turn their heads faster than a rollercoaster. Now, I may have seen my fair share of wacky collaborations in my day, but the camaraderie...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 2

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading
Early Orders Key for Custom Kids' Gifts This Season

Updated Category News Views 1

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Continue Reading
Potensic's ATOM 3 Invites Drone Creators to 'See Beyond'

Updated Category News Views 3

Innovative Features of Potensic's New Drone Potensic decided to shake things up a bit this year at IFA Berlin, showcasing their new creation: the ATOM 3 drone. Under the theme "SEE BEYOND," Potensic’s message to creators was clear—there’s more to explore in the world of visual storytelling than meets the eye. This drone isn't just another gadget; it's an invitation...

Continue Reading
Huion Kamvas Pad 12: A Creative Power Tool

Updated Category News Views 3

The Kamvas Pad 12 Hits the Market In a crowded tablet market that's fierce with innovation, Huion tossed their latest tool into the ring—the Kamvas Pad 12. Now, anyone who’s been watching the digital art scene won't be surprised that Huion, with its decade and a half of digital prowess, is pulling another tablet trick out of its hat. Key Features and Innovations If...

Continue Reading
CalExitNow Fights Federal Interference in CA Elections

Updated Category News Views 2

California's Election Integrity: A Ticking Time Bomb Strap in for a bumpy ride, folks—California might soon find its electoral process caught in a Washington whirlwind. CalExitNow, the group advocating for California's independence, is sounding alarms about looming federal interventions that could shake the state's democratic foundations. The Federal Storm Rolling In...

Continue Reading

Top 5 Most Recently Viewed Articles

CEO Confidence: Understanding Dolphin Entertainment's Stock Moves

Updated Category News Views 114

CEO Insights: Motivation Behind Stock Accumulation In the world of investing, the actions of company insiders often speak louder than words. While public statements and press releases paint a picture, nothing quite conveys confidence like a CEO investing their own money into their company's stock. This trend is particularly evident at Dolphin Entertainment, where CEO...

Continue Reading
Insights on AR/VR Market Growth and Competitive Landscape

Updated Category News Views 130

Meta's Dominating Role in the AR/VR Market According to recent data, global shipments of AR/VR headsets have seen a remarkable rebound, marking a significant growth of 12.8%. After facing declines for two consecutive quarters, the industry is witnessing an upswing that can largely be attributed to the innovations and market strategies of a leading player: Meta. Market...

Continue Reading
Investigation into Fortinet, Inc.: Shareholder Concerns Rise

Updated Category News Views 263

Overview of the Investigation into Fortinet, Inc. Pomerantz LLP is currently conducting an investigation into Fortinet, Inc. (NASDAQ: FTNT), focusing on potential claims by investors. This inquiry aims to uncover any alleged involvement of the company's officers or directors in securities fraud or other unlawful business practices that may affect shareholder interests....

Continue Reading
Umicore Reports Key Shareholding Changes from Bank of America

Updated Category News Views 252

Notification from Bank of America Corporation to Umicore Umicore has received a transparency notification from Bank of America Corporation that highlights a critical change in their shareholding structure. This notification, dictated by legal obligations regarding significant ownership stakes, reveals that Bank of America has surpassed the 3% threshold in its direct...

Continue Reading
Aalberts N.V. Posts Q3 2025 Financial Results and Outlook

Updated Category News Views 330

Aalberts N.V. Financial Overview for Third Quarter 2025 Aalberts N.V. has reported its financial results for the third quarter of 2025, showcasing a total revenue of EUR 772.5 million. This reflects a 1.9% organic revenue decline compared to the same period last year. The company also achieved an EBITA of EUR 96.3 million, which corresponds to a margin of 12.5%. Market...

Continue Reading